High-throughput ultrafiltration process for most protein, nucleic acid, and biomolecular nanoparticle samples!
AcroPrep filter plates can perform high-throughput ultrafiltration processes for protein and nucleic acid samples, viral vectors, and extracellular vesicles. They utilize modified PES as the ultrafiltration membrane and support a wide range of MWCO (molecular weight cut-off) from 1K to 100K. Additionally, they have low protein binding properties, contributing to high recovery rates of samples. The filter plates are available in three formats: 24, 96, and 384 wells. When selecting the MWCO, it is recommended to choose a MWCO that is 1/3 to 1/6 times the molecular weight of the protein to be retained when concentrating proteins. For recovering the filtrate, it is advisable to select a membrane with an MWCO that is 3 to 6 times that of the target protein. We are distributing samples for free, so please indicate your desired number of wells and MWCO value in the inquiry section. In the FASP method, it is used for chemical modifications of purified proteins and washing of reaction reagents on a 96-well ultrafiltration membrane. Reference: Potriquet, J., et al., PLOS ONE 12 e0175967 (2017)
Inquire About This Product
Related Videos
basic information
Target Products ■ 24-Well Filter Plate, 7 mL Omega Membrane (1K, 3K, 10K, 30K, 100K) ■ 96-Well Filter Plate, 350 µL Omega Membrane (3K, 10K, 30K, 100K) ■ 96-Well Filter Plate, 1 mL Omega Membrane (3K, 10K, 30K, 100K) ■ 384-Well Filter Plate, 100 µL Omega Membrane (10K, 30K, 100K)
Price information
For inquiries regarding delivery dates and prices, please use the inquiry form or the contact button.
Delivery Time
Applications/Examples of results
High-throughput ultrafiltration of proteins and nucleic acids. ■ Concentration and purification of proteins ■ Purification of nucleic acids ■ Cleaning of PCR products ■ Cleaning of labeled molecules
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
